Abstract: An assembly integrates an aft wing spar root fitting to an aircraft fuselage when joining the aircraft wing to the aircraft body. The assembly provides structural strength to the connection between the aircraft wing and the aircraft body, provides corrosion prevention and provides improved inspection capabilities and repair capabilities to the aircraft wing and aircraft body connection.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.

Abstract: Disclosed are compositions and methods for targeted treatment of cancers, such as TLR9-expressing cancers. In particular, molecules containing a TLR9 targeting ligand, such as a CpG oligodeoxynucleotide, that target lytic peptides to TLR9-expressing malignant cells are disclosed.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.

Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatment of cancer.

Abstract: The present invention generally relates to compositions including six membered heterocyclic 1,4-diaza-2-one moieties covalently bonded by a hydrazine bond and processes for producing the same. The compositions of the present invention may be utilized as peptido- and/or proteomimetics, for example,' in connection with alpha-helical proteins, like Bcl-2 proteins.

Abstract: Novel peptides are disclosed that may be used as inhibitors of amyloidogenesis, as suppressors of amyloid toxicity, and as therapeutic agents for amyloid-associated diseases such as Alzheimer's disease, Parkinson's Disease, Creutzfeldt-Jakob Disease, Huntington's Disease, and Type II Diabetes. These new ?-strand mimics (?-sheet “blockers”), containing C?,?-disubstituted amino acids, specifically interact with and block the development of the ?-sheet structure of the developing fibrils of amyloid diseases, such as Alzheimer's disease amyloid ?-peptide (A?). We have discovered that oligomerization of ?-sheet structures, including those implicated in amyloid-associated diseases, may be inhibited or even reversed by the presence of extended peptide structures that have only one edge available for hydrogen bonding. Without a second edge that is also available for hydrogen bonding, the extension of a developing ?-sheet is blocked by binding to the novel peptides.

Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% ?,?-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar ?,?-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.

Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.

Abstract: “Minimalist” antimicrobial peptides are disclosed based on 50 to 80% &agr;,&agr;-dialkylated amino acids. The peptides are short, cationic, amphipathic, and possess a high helix propensity. Polar &agr;,&agr;-dialkylated amino acids are also disclosed. These peptides are easy and inexpensive to synthesize via solid-phase techniques. The peptides exhibit in vitro anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides exhibit in vivo bioactivity against intracellular pathogens.

Abstract: Minimalist lytic peptides are disclosed that may be readily synthesized on a large scale via a highly-convergent, solution-phase synthesis. The peptides are amphipathic, and are easy and inexpensive to synthesize via solution phase techniques. The peptides exhibit anti-bacterial properties at concentrations that are not lethal to normal mammalian cells. The peptides comprise multimers, i.e. two or more repeats, of certain heptads of amino acid residues. The heptads were designed to generate amphipathic peptides when the heptads are combined into multimers, and were further designed to be readily suited for convergent, solution-phase synthesis. The preferred heptads are described generically by one of the following four formulas, in which "Xps" denotes a positively charged amino acid at physiological pH, and in which "Xnp" denotes a nonpolar amino acid at physiological pH: (1) Xps.sub.1 Xnp.sub.1 Xnp.sub.2 Xps .sub.1 Xnp.sub.1 Xnp.sub.2 Xps, or (2) XpsXnp.sub.1 Xnp.sub.2 Xps.sub.1 Xnp.sub.1 Xnp.sub.2 Xps.sub.

Abstract: Condensed dimer alcohols, also known as Guerbet alcohols, are prepared using metal alkoxide as the catalyst by reacting alcohol with saturated or unsaturated aldehyde or allyl alcohol, or mixtures thereof, at 100.degree.-220.degree. C. and removing water as it is formed during the reaction. Dimer alcohols are prepared in high yields without the need for a transition metal catalyst.